Teresa P DiLorenzo

Title: The Innovative Contributions of Teresa P. DiLorenzo

Introduction

Teresa P. DiLorenzo, based in Bayside, NY, is a prominent inventor known for her significant contributions to the field of medical science, particularly regarding type 1 diabetes. With a total of two patents to her name, DiLorenzo's work focuses on innovative treatments and methodologies that address the challenges posed by autoimmune diseases.

Latest Patents

DiLorenzo's latest patents delve into the identification and application of antigens that are targeted by pathogenic T cells in type 1 diabetes. The first patent emphasizes the discovery of a dominant ligand for CD8T cells associated with this autoimmune condition. It identifies the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) as a critical component. The invention outlines various oligopeptide and polypeptide compositions, such as:

- YLKTN(A/I/L/V)FL (SEQ ID NO:3)

- FLWSVFWLI (SEQ ID NO:4)

- (T/A)YY(G/T)FLNFM (SEQ ID NO:5)

- LR(L/V)(F/L)(G/N)IDLL (SEQ ID NO:6)

- KWCANPDWI (SEQ ID NO:7)

- SFCKSASIP (SEQ ID NO:8)

These compositions are designed to bind with human MHC class I molecules and offer potential therapeutic methods for treating mammals at risk of or suffering from type 1 diabetes. The second patent similarly provides oligopeptide antigens for AI4-like T cells, along with methods for determining diabetes risk and treating affected individuals.

Career Highlights

Throughout her career, Teresa P. DiLorenzo has made significant strides in diabetes research. Her affiliations with esteemed institutions such as Albert Einstein College of Medicine and the University of Virginia have facilitated her groundbreaking work. These roles have allowed her to explore innovative avenues for potential treatments, significantly impacting the scientific community.

Collaborations

DiLorenzo has collaborated with notable professionals in her field, including Scott M. Lieberman and Anne M. Evans. These partnerships have played a crucial role in advancing her research and expanding the impact of her inventions in medical science.

Conclusion

Teresa P. DiLorenzo's contributions to the study of type 1 diabetes exemplify the power of innovation in addressing complex medical challenges. Her patents not only reveal sophisticated technical knowledge but also hold promise for future advancements in therapeutic strategies for autoimmune diseases. As she continues to develop her research, her work will undoubtedly inspire and lead to further innovations in the medical field.